189 related articles for article (PubMed ID: 11929795)
1. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
[TBL] [Abstract][Full Text] [Related]
2. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
3. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
[TBL] [Abstract][Full Text] [Related]
4. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of deferoxamine-based nanochelator in rats.
Jones G; Zeng L; Stiles WR; Park SH; Kang H; Choi HS; Kim J
Nanomedicine (Lond); 2022 Sep; 17(22):1649-1662. PubMed ID: 36547231
[TBL] [Abstract][Full Text] [Related]
6. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
7. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture.
Hershko C; Konijn AM; Nick HP; Breuer W; Cabantchik ZI; Link G
Blood; 2001 Feb; 97(4):1115-22. PubMed ID: 11159545
[TBL] [Abstract][Full Text] [Related]
8. Renal clearable nanochelators for iron overload therapy.
Kang H; Han M; Xue J; Baek Y; Chang J; Hu S; Nam H; Jo MJ; El Fakhri G; Hutchens MP; Choi HS; Kim J
Nat Commun; 2019 Nov; 10(1):5134. PubMed ID: 31723130
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
Hershko C; Grady RW; Link G
Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
Emara AM; El Kelany RS; Moustafa KA
Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
[TBL] [Abstract][Full Text] [Related]
12. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
13. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
14. Oral iron chelators.
Cappellini MD; Pattoneri P
Annu Rev Med; 2009; 60():25-38. PubMed ID: 19630568
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a novel iron chelator (HBED; (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis).
Sullivan KE; Lavin SR; Livingston S; Knutson M; Valdes EV; Warren LK
J Anim Physiol Anim Nutr (Berl); 2022 Sep; 106(5):1107-1117. PubMed ID: 35894091
[TBL] [Abstract][Full Text] [Related]
17. Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy.
Obejero-Paz CA; Yang T; Dong WQ; Levy MN; Brittenham GM; Kuryshev YA; Brown AM
J Lab Clin Med; 2003 Feb; 141(2):121-30. PubMed ID: 12577048
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update.
Franchini M; Gandini G; Veneri D; Aprili G
Blood; 2004 Jan; 103(2):747-8. PubMed ID: 14702291
[No Abstract] [Full Text] [Related]
20. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC
IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
